You are viewing the site in preview mode

Skip to main content

Table 3 Patient-reported outcomes at W8 compared to D0

From: Evaluation of the effect of multipoint intra-mucosal vaginal injection of a specific cross-linked hyaluronic acid for vulvovaginal atrophy: a prospective bi-centric pilot study

Outcome D0 W8 p value
Pain/dyspareunia VAS (N20)
VAS    
 Median 7.25 0 p = 0.0001
 IQR 3.5; 8.25 0; 3.25  
 Range 0; 10 0; 10  
Number of women reporting Dyspareunia (N = 20)
Suffer with Dyspareunia 16 8 p = 0.0078
Number of women reporting Vaginal dryness (N = 20)
Suffer with dryness 16 2 p = 0.0005
Number of women reporting Vaginal Chaffing (N = 20)
Suffer with chaffing 10 2 p = 0.0215
Number of women reporting Vulvar pruritus (N = 20)
Suffering with pruritus 7 1 p = 0.0313
Female sexual function index (FSFI) scores
Full scale
 Median 18.8 24.65 p = 0.0019
 IQR 15.7; 21.9 19.9; 28.7  
 Range 2; 28.8 4.8; 34.5  
Desire domain
 Median 3 3.6 p = 0.0010
 IQR 1.8; 3.6 2.7; 4.2  
 Range 1.2; 4.2 1.8; 5.4  
Arousal domain
 Median 3 4.2 p = 0.0549
 IQR 1.5; 4.5 2.55; 4.8  
 Range 0; 5.1 0; 5.7  
Lubrication domain
 Median 2.4 4.65 p = 0.0005
 IQR 0.6; 3 3.75; 5.1  
 Range 0; 6 0; 6  
Orgasm domain
 Median 3.8 4.8 p = 0.3515
 IQR 0.6; 5.6 1.8; 5.6  
 Range 0; 6 0; 6  
Satisfaction domain
 Median 4 5.2 p = 0.0126
 IQR 2.8; 4.8 4; 5.6  
 Range 0.8; 6 1.2; 6  
Pain domain*
 Median 1.6 3.6 p = 0.0005
 IQR 0; 3.6 1.2; 5.4  
 Range 0; 4.8 0; 6  
  1. *A higher score indicates less pain